Abstract
Prostate cancer is the most common cancer in men in the United States and is the second most common cause of death. While treatment options in early stage disease are curative in intent, treatment of metastatic prostate cancer remains challenging. Although, several new and promising treatment options exploiting novel targets have permeated the therapeutic landscape in recent years, another viable target for therapy is tumor angiogenesis. Many antiangiogenic agents are under development and some are currently under investigation in clinical trials.
Copyright © 2014 S. Karger AG, Basel.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Angiogenic Proteins / antagonists & inhibitors*
-
Angiogenic Proteins / genetics
-
Angiogenic Proteins / metabolism
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Cell Movement
-
Clinical Trials as Topic
-
Endothelial Cells / drug effects
-
Endothelial Cells / metabolism
-
Endothelial Cells / pathology
-
Gene Expression Regulation
-
Humans
-
Immunologic Factors / therapeutic use
-
Male
-
Neovascularization, Pathologic / prevention & control*
-
Prostatic Neoplasms / blood supply*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology
-
Signal Transduction
Substances
-
Angiogenesis Inhibitors
-
Angiogenic Proteins
-
Antineoplastic Agents
-
Immunologic Factors